Company Overview
Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.
Recent News
Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions
Propanc Biopharma Announces No Immediate Plans for Reverse Stock Split
Propanc Biopharma’s CSO Hails Dostarlimab’s Impressive Results Whilst Acknowledging More Work to Be Done in the Fight Against Cancer
Stock Overview
07/05/2022 03:59 PM EDT
Investor Relations
Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com